Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccines

June 1, 2026 10:39 AM EDT News Briefing Agios li­cens­es Os­cotec drug; CEPI funds three po­ten­tial Ebo­la vac­cines ENDPOINTS 🪪 Agios li­cens­es Os­cotec’s im­mune throm­bo­cy­tope­nia drug: Agios is pay­ing $25 mil­lion up­front for ex­clu­sive glob­al rights to Os­cotec’s next-gen­er­a­tion … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER